Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
Latest Information Update: 06 May 2024
At a glance
- Drugs Axitinib (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 01 May 2024 Planned primary completion date changed from 6 Apr 2024 to 6 Oct 2024.
- 01 May 2024 Status changed from recruiting to active, no longer recruiting.
- 15 May 2023 Planned End Date changed from 6 Apr 2024 to 6 Apr 2025.